Industry corner: perspectives and controversies - The challenges of patient access to new medicines.
Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany.
C-N
CN
Gann
Boehringer Ingelheim Corporation, Reims, France.
N
N
Morsli
Boehringer Ingelheim Pharmaceuticals GmbH & Co. KG, Biberach, Germany.
R
R
Kaiser
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077143:Docetaxel; D004345:Drug Industry; D015507:Drugs, Investigational; D005062:European Union; D006297:Health Services Accessibility; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D020380:Needs Assessment; D043823:Taxoids / Q000008:administration & dosage
D015507:Drugs, Investigational; D007211:Indoles; D043823:Taxoids; D000077143:Docetaxel; C530716:nintedanib